Meropenem Bradex (Meropenem Anhydrous)

Meropenem Bradex is a broad‑spectrum carbapenem used to treat severe bacterial infections in hospitalized patients.

• Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure.
• Complicated urinary tract infections: provides rapid microbiological clearance.
• Nosocomial pneumonia: improves respiratory outcomes and reduces mortality.
• Meningitis: penetrates the cerebrospinal fluid to eradicate causative pathogens.
• Severe sepsis and septic shock: offers bactericidal activity essential for hemodynamic stabilization.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic lysis and rapid bactericidal activity against a wide range of Gram‑positive, Gram‑negative and anaerobic organisms.

Adverse reactions may occur with meropenem therapy and should be monitored.

Common Side Effects

• Nausea: mild to moderate gastrointestinal discomfort.
• Diarrhea: may be watery and self‑limiting.
• Vomiting: occasional episodes after infusion.
• Headache: transient and usually resolves.
• Rash: erythematous skin eruption.
• Infusion site reactions: pain or erythema at the injection site.

Serious or Rare Side Effects

• Seizures: increased risk in patients with CNS disorders or renal impairment.
• Anaphylaxis: severe hypersensitivity requiring immediate medical attention.
• Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis.
• Neutropenia: marked reduction in white blood cells.
• Thrombocytopenia: low platelet count leading to bleeding risk.
• Acute renal failure: worsening kidney function in susceptible individuals.

Prior to initiating meropenem, clinicians should assess patient‑specific risk factors and monitor for adverse events.

• Renal function: adjust dose in patients with impaired renal clearance.
• Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactams.
• Pregnancy: use only when the potential benefit justifies the potential risk to the fetus.
• Valproic acid co‑administration: monitor for reduced plasma levels of valproate.
• Seizure risk: observe patients with a history of epilepsy or CNS disorders.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: meropenem reduces valproate concentrations, increasing seizure risk.
• CNS depressants: additive effect may lower seizure threshold.
• Probenecid: may increase meropenem plasma levels, heightening toxicity.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: combined use can enhance nephrotoxicity.
• Loop diuretics: may increase risk of ototoxicity when used together.
• Anticoagulants (e.g., warfarin): monitor INR for potential alterations in anticoagulant effect.